Liquidity remains supported by $18.6 million in cash reserves, though the firm's reliance on provincial procurement cycles may continue to strain operational cash conversion.
| Metric | Dec'24 | Dec'23 | Dec'22 | Dec'21 |
|---|
| Cash from Operations | 41.05M | 48.18M | 17.34M | 31.81M |
| Operating CF Margin % | 22.03% | 22.77% | 6.66% | 14.86% |
| Operating CF Growth % | -14.81% | 177.96% | -45.5% | - |
| Net Income | 13.47M | 37.51M | 55.74M | 46.47M |
| Depreciation & Amortization | 24.16M | 23.91M | 18.8M | 16.01M |
| Stock-Based Compensation | 0 | 0 | 0 | 0 |
| Deferred Taxes | 924K | 758K | -1.09M | -358K |
| Other Non-Cash Items | 3.47M | 6.5M | 10.7M | 3.4M |
| Working Capital Changes | -977K | -20.49M | -66.82M | -33.71M |
| Change in Receivables | 11.31M | 38.05M | -47.38M | -40.91M |
| Change in Inventory | -5.88M | -12.9M | -12.32M | -12.34M |
| Change in Payables | -404K | -35.61M | -9.67M | 17.63M |
| Cash from Investing | -27.66M | -11.77M | -27.33M | -26.27M |
| Capital Expenditures | -13.59M | -7.4M | -27.33M | -19.06M |
| CapEx % of Revenue | 7.29% | 3.49% | 10.5% | 8.9% |
| Acquisitions | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - |
| Other Investing | -14.08M | -3.15M | 0 | -7.21M |
| Cash from Financing | -22.13M | -18.98M | 13.46M | -3.05M |
| Debt Issued (Net) | -2.74M | 24.97M | 34.88M | 8M |
| Equity Issued (Net) | 0 | 0 | 0 | 0 |
| Dividends Paid | -16.02M | -39.45M | -21.43M | -11.05M |
| Share Repurchases | 0 | 0 | 0 | 0 |
| Other Financing | -3.37M | -4.5M | 0 | 0 |
| Net Change in Cash | -8.58M | 17.44M | 3.46M | 2.49M |
| Free Cash Flow | 13.27M | 36.58M | -9.99M | 5.41M |
| FCF Margin % | 7.12% | 17.29% | -3.84% | 2.53% |
| FCF Growth % | -63.72% | 466.1% | -284.75% | - |
| FCF per Share | 0.29 | - | - | - |
| FCF Conversion (FCF/Net Income) | 3.63x | 1.53x | 0.37x | 0.82x |
| Interest Paid | 3.98M | 4.42M | 2.84M | 1.05M |
| Taxes Paid | 116K | 10.49M | 8.48M | 6.99M |
Swine cycle demand volatility
As the company lacks granular cash flow disclosure, the relationship between net income and operating cash flow remains opaque, though the 6.07% net margin suggests that any divergence between accounting profits and actual cash generation warrants significant caution regarding the sustainability of reported earnings for ZYBT.
The thin net margin profile implies that even minor discrepancies in revenue recognition or accrual management could lead to a material disconnect between reported profitability and cash reality. Investors should monitor whether the company's reliance on government procurement tenders results in extended collection cycles that suppress operating cash flow relative to net income.
Based on the firm's specialized biological manufacturing requirements, ZYBT must commit significant capital to maintain its P3 laboratory certifications, which likely consumes a substantial portion of cash flow and limits the company's ability to pivot toward more aggressive growth initiatives in the current market environment.
The necessity of maintaining sterile, high-security production environments creates a high fixed-cost burden that effectively functions as mandatory maintenance capex. This capital intensity appears to be a structural constraint that limits the company's financial flexibility during periods of revenue contraction.
According to industry norms for the Chinese veterinary sector, ZYBT's reliance on provincial government procurement contracts likely creates significant working capital pressure, as extended payment terms often delay cash conversion and necessitate careful management of the company's $18.6 million cash reserve to maintain operational stability.
The lumpy nature of government tender fulfillment suggests that cash flow may be subject to seasonal volatility, complicating short-term liquidity planning. If the company fails to accelerate collections from these public sector clients, it may face increasing pressure on its working capital cycle despite its low debt-to-equity ratio.
With a debt-to-equity ratio of 0.25%, ZYBT appears to prioritize balance sheet preservation over aggressive capital deployment, though the recent 11.95% revenue decline suggests that this conservative stance may be hindering the company's ability to successfully diversify its product mix or expand into new commercial markets.
The company's current cash position provides a buffer, yet the lack of evidence regarding strategic reinvestment suggests that management may be struggling to identify high-return opportunities. Investors should monitor whether this capital remains underutilized or if it will be deployed to address the company's declining market share.
Quick answers to the most common questions about buying ZYBT stock.
Zhengye Biotechnology Holding Limited (ZYBT) generated $41.0M in net cash from operating activities in 2024. This reflects the cash generated directly from core business operations.
Zhengye Biotechnology Holding Limited (ZYBT) generated $13.3M in free cash flow in 2024. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Zhengye Biotechnology Holding Limited (ZYBT) spent $13.6M on capital expenditures in 2024. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2024, Zhengye Biotechnology Holding Limited (ZYBT) returned $16.0M to shareholders via cash dividends. This shows the company's commitment to returning capital to its equity investors.